Search

Your search keyword '"Hépatologie Gastro-Entérologie"' showing total 71 results

Search Constraints

Start Over You searched for: Author "Hépatologie Gastro-Entérologie" Remove constraint Author: "Hépatologie Gastro-Entérologie" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
71 results on '"Hépatologie Gastro-Entérologie"'

Search Results

1. Transplantation fécale chez un enfant via une sonde de gastrojéjunostomie pour une infection récurrente à Clostridium difficile

3. Stress management in obesity during a thermal spa residential programme (ObesiStress): protocol for a randomised controlled trial study

4. High-frequency ultrasound quantification of acute radiation dermatitis: pilot study of patients undergoing radiotherapy for breast cancer

5. Top-down Versus Step-up Strategies to Prevent Postoperative Recurrence in Crohn’s Disease

6. Safety, pharmacokinetic, and pharmacodynamic study of sibofimloc, a novel FimH blocker in patients with active Crohn's disease

7. Prevalence of Self-Reported Venous Thromboembolism and Cardiovascular Risk Factors in Patients with Ulcerative Colitis: The GETAID FOCUS Study

8. Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease

9. Thrombin Generation and Cirrhosis

10. Implementation and short-term adverse events of anti-SARS-CoV-2 vaccines in inflammatory bowel disease patients: an international web-based survey

11. Non-invasive biomarkers of non-alcoholic fatty liver disease in patients with Metabolic Syndrome: insights from the RESOLVE study

12. Implementation and Short-term Adverse Events of Anti-SARS-CoV-2 Vaccines in Inflammatory Bowel Disease Patients: An International Web-based Survey

13. Role of adherent and invasive Escherichia coli in Crohn’s disease: lessons from the postoperative recurrence model

14. Real‐world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti‐ TNF agent

15. Comparison of the risk of Crohn's disease postoperative recurrence between modified Rutgeerts score i2a and i2b categories: an individual patient data meta-analysis

16. Impact of HIV Infection on the Course of Inflammatory Bowel Disease and Drug Safety Profile: A Multicenter GETAID Study

17. Comparative acceptability of therapeutic maintenance regimens in patients with inflammatory bowel disease: results from the nationwide ACCEPT2 Study

18. Role of adherent and invasive E. coli in Crohn's Disease: Lessons from the postoperative recurrence model

19. Impact of the Ileal Microbiota on Surgical Site Infections in Crohn's Disease: A Nationwide Prospective Cohort

20. Vedolizumab Therapy is Ineffective for Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A GETAID Multicentre Cohort Study

21. Anti-TNF agents restrict adherent-invasive E. coli replication within macrophages through modulation of chitinase 3-like 1 in patients with Crohn’s disease

22. Yersiniabactin siderophore of Crohn’s disease-associated adherent-invasive Escherichia coli Is Involved in autophagy activation in host cells

23. Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy

24. Current practice of pressurized intraperitoneal aerosol chemotherapy (PIPAC): Still standardized or on the verge of diversification?

25. Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or Cyclosporine

26. Transmural healing and MRI healing are associated with lower risk of bowel damage progression than endoscopic mucosal healing in Crohn's disease

27. Effectiveness and safety of ustekinumab intensification at 90 Mg every four weeks In Crohn's disease: a multicenter study

28. Five-Year Survival Outcomes of Hybrid Minimally Invasive Esophagectomy in Esophageal Cancer

29. Phase 3, Multicenter Open‐Label study to investigate the efficacy of elbasvir and grazoprevir fixed‐dose combination for 8 weeks in treatment‐naïve, HCV GT1b‐infected patients, with non‐severe fibrosis

30. Variation of faecal calprotectin level within the first three months after bowel resection is predictive of endoscopic postoperative recurrence in Crohn's disease

31. Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication

32. Systematic Review With Meta-Analysis: Anti-TNF Therapy in Refractory Pouchitis and Crohn’s Disease-Like Complications of the Pouch After Ileal Pouch-Anal Anastomosis Following Colectomy for Ulcerative Colitis

33. Macrophages Inability to Mediate Adherent-Invasive E. coli Replication is Linked to Autophagy in Crohn’s Disease Patients

34. Tissue-Specific Oxidative Stress Modulation by Exercise: A Comparison between MICT and HIIT in an Obese Rat Model

35. The variation of faecal calprotectin level within the first months after bowel resection is predictive of endoscopic postoperative recurrence in patients with Crohn's disease

36. Effectiveness and safety of ustekinumab 90 mg every 4 weeks in Crohn's disease

37. Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy

38. Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Vedolizumab in Patients With Refractory Ulcerative Colitis

39. High intensity interval training promotes total and visceral fat mass loss in obese Zucker rats without modulating gut microbiota

40. Effects of a short residential thermal spa program to prevent work-related stress/burnout on stress biomarkers: a proof of concept study

41. Preventive Effect of Spontaneous Physical Activity on the Gut-Adipose Tissue in a Mouse Model That Mimics Crohn’s Disease Susceptibility

42. Dust evolution across the Horsehead nebula

43. Human Hepatocellular Carcinoma Metabolomic Profile in Non Alcoholic Fatty Liver Disease (NAFLD) According to Severity of Fibrosis

44. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs

45. The epidemiology of Budd–Chiari syndrome in France

46. Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study

47. Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients

48. Increased factor VIII plays a significant role in plasma hypercoagulability phenotype of patients with cirrhosis

49. Augmented reality guidance in laparoscopic hepatectomy with deformable semi-automatic computed tomography alignment (with video)

50. Cholangiopathy in critically ill patients surviving beyond the intensive care period: a multicentre survey in liver units

Catalog

Books, media, physical & digital resources